MURRAY HILL, N.J., Jul 8, 2003 (BUSINESS WIRE) -- C. R. Bard, Inc.
(NYSE:BCR) today announced that its wholly-owned subsidiary, Bard
Access Systems, Inc., received Food and Drug Administration clearance
to market the HemoSplit(TM) catheter for long-term renal dialysis
care. Bard Access Systems previously acquired the exclusive rights to
this patented technology invented by Dr. Thierry Pourchez, a noted
French surgeon.
Long-term dialysis catheters are used to provide indwelling
vascular access to end-stage renal-disease patients requiring
dialysis treatments. These patients suffer from reduced kidney
function, and require cleansing of their blood by a dialysis machine.
The HemoSplit catheter is designed to deliver exceptional flow
performance due to its robust materials, large lumens and
non-restrictive patented, fixed split-tip design.
"The approval of our HemoSplit catheter complements our leadership
position in the vascular access market and strengthens our dialysis
line within that segment," commented William H. Longfield, chairman
and chief executive officer, "further, it demonstrates our proven
ability to develop new and innovative products to enhance and improve
the quality of life."
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
New Jersey, is a leading multinational developer, manufacturer and
marketer of health care products in the fields of vascular, urology,
oncology and surgical specialty products.
This press release contains forward-looking statements, the
accuracy of which is necessarily subject to risks and uncertainties.
Please refer to our March 31, 2003, Form 10-Q for a statement with
regard to forward-looking statements, including disclosure of
additional factors that could cause actual results to differ
materially from those expressed or implied.
SOURCE: C. R. Bard, Inc.
C. R. Bard, Inc.
Investor Relations:
Eric J. Shick, 908/277-8413
or
Media Relations:
Holly P. Glass, 703/754-2848
http://www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.
|
